"The end of a discretionary enforcement period for regenerative medicine products was pushed back by another 6 months, according to a final guidance issued today by the US Food and Drug Administration (FDA)." Associate Professor of the Center for Bioethics Leigh Turner, PhD adds: “This extension doubles down on a misguided approach to a marketplace that has for a decade needed more robust oversight by the FDA.”
